SV

Street Verdict

Analyst Scorecard

A record of what ETMarkets Analysis said publicly, with the source. Not advice.

“Short-term traders are advised to buy Aurobindo Pharma stock, targeting ₹1,500 in the medium-term. The stock has rebounded from multi-year support levels around ₹1,100, aligning with a channel line from October 2016, and is currently trading above its 5, 10, 30, 50, and 200-DMA, indicating strength.”

ETMarkets Analysis’s track record (trackable calls only): 193 graded calls · 95% CI 23–35%

Aurobindo Pharma LtdBullishCalled 06 Jan 2025Graded 06 Apr 2025
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹1,500, as stated.

Window: 90 days, from the call's own horizon word ("in the medium-term").

Neither the target ₹1,500 was reached on a close by the end of the window. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹1297.5 on 2025-01-07 (next trading session's close); neither target nor stop reached by window end 2025-04-06. Window 90 days — rule H4: the quote says "in the medium-term" (short-term 30 days, medium-term 90, long-term 12 months).

Tracking Aurobindo Pharma Ltd since this call

1-year tracking window
Read the original articleSee ETMarkets Analysis’s full track record